Structure-Based Drug Design for Targeting IRE1: An in Silico Approach for Treatment of Cancer
Drug Research · 01.02.2024 · 74 (02) · 81-88
DOI: 10.1055/a-2211-2218 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Research, erschienen am 01.02.2024. Verfasst von Alireza Poustforoosh und 4 weiteren Autor:innen. Beteiligte Einrichtung: Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. Hauptthemen laut MEDLINE: Protein Serine-Threonine Kinases, Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 49 Literaturangaben.
Abstract (Originalsprache)
Background
Endoplasmic Reticulum (ER) stress and Unfolded Protein Response (UPR) play a key role in cancer progression. The aggregation of incorrectly folded proteins in the ER generates ER stress, which in turn activates the UPR as an adaptive mechanism to fix ER proteostasis. Inositol-requiring enzyme 1 (IRE1) is the most evolutionary conserved ER stress sensor, which plays a pro-tumoral role in various cancers. Targeting its’ active sites is one of the most practical approaches for the treatment of cancers.
Objective
In this study, we aimed to use the structure of 4μ8C as a template to produce newly designed compounds as IRE1 inhibitors.
Methods
Various functional groups were added to the 4μ8C, and their binding affinity to the target sites was assessed by conducting a covalent molecular docking study. The potential of the designed compound for further in vitro and in vivo studies was evaluated using ADMET analysis.
Results
Based on the obtained results, the addition of hydroxyl groups to 4μ8C enhanced the binding affinity of the designed compound to the target efficiently. Compound 17, which was constructed by the addition of one hydroxyl group to the structure of 4μ8C, can construct a strong covalent bond with Lys907. The outcomes of ADMET analysis indicated that compound 17 could be considered a drug-like molecule.
Conclusion
Our results revealed that designed compound 17 could inhibit IRE1 activity. Therefore, this designed compound is a remarkable inhibitor of IRE1 and introduces a promising therapeutic strategy for cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
- Applied Cellular and Molecular Research Center, Kerman University of Medical Sciences, Kerman, Iran.
- Department of Clinical Biochemistry, Afzalipour School of Medicine, Kerman University of Medical Sciences, Kerman, Iran.
- Department of Chemical Engineering, Faculty of Engineering, Shahid Bahonar University of Kerman, Kerman, Iran.
ORCID-Profile: Mohammad Hadi Nematollahi
Zitieren
APA
Poustforoosh, A., Faramarz, S., Nematollahi, M. H., Mahmoodi, M., & Azadpour, M. (2024). Structure-Based Drug Design for Targeting IRE1: An in Silico Approach for Treatment of Cancer. Drug Research, 74(02), 81-88. https://doi.org/10.1055/a-2211-2218
Vancouver
Poustforoosh A, Faramarz S, Nematollahi MH, Mahmoodi M, Azadpour M. Structure-Based Drug Design for Targeting IRE1: An in Silico Approach for Treatment of Cancer. Drug Research. 2024;74(02):81-88. doi:10.1055/a-2211-2218
BibTeX
@article{Poustforoosh2024,
author = {Poustforoosh, Alireza and Faramarz, Sanaz and Nematollahi, Mohammad Hadi and Mahmoodi, Mehdi and Azadpour, Mahdiyeh},
title = {Structure-Based Drug Design for Targeting IRE1: An in Silico Approach for Treatment of Cancer},
journal = {Drug Research},
year = {2024},
volume = {74},
number = {02},
pages = {81--88},
doi = {10.1055/a-2211-2218}
}
EUVIMED